Piperacillin/tazobactam versus cefotaxime plus metronidazole for the treatment of severe intra-abdominal infection in hospitalized pediatric patients

Current Therapeutic Research - Clinical and Experimental

Volumn 62, Issue 6, 2001, Pages 488-502

  Adam, Dieter ^a   Linglöf, Thomas ^b   Floret, Daniel ^c   Kirsch, Ted ^d  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c EDOUARD HERRIOT HOSPITAL   (France)

^d Wyeth Pharma GmbH   (Germany)

Author keywords

Cefotaxime; Intra abdominal infection; Metronidazole; Pediatric; Piperacillin tazobactam

Indexed keywords

CEFOTAXIME; METRONIDAZOLE; PIPERACILLIN PLUS TAZOBACTAM;

ABDOMINAL ABSCESS; ANTIBIOTIC THERAPY; APPENDICITIS; ARTICLE; BACTERIAL PERITONITIS; BRONCHITIS; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; FEMALE; FEVER; HOSPITAL PATIENT; HUMAN; INTESTINE PERFORATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHARYNGITIS; PRESCHOOL CHILD; PRIORITY JOURNAL; PSEUDOMONAS; RANDOMIZED CONTROLLED TRIAL; RASH; SCHOOL CHILD; VOMITING;

EID: 0034979455     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(01)80059-X     Document Type: Article

References (36)

1. Piperacillin-tazobactam versus imipenemcilastatin for treatment of intra-abdominal infections
2. A randomized multicenter trial of piperacillin/tazobactam versus imipenem/cilastatin in the treatment of severe intra-abdominal infections
3. Piperacillin/tazobactam versus imipenem/cilastatin in the treatment of intra-abdominal infections
4. Results of the North American trial of piperacillin/tazobactam compared with clindamycin and gentamicin in the treatment of severe intra-abdominal infections
5. Efficacy and safety of piperacillin/tazobactam in intraabdominal infections
6. Piperacillin/tazobactam in comparison with clindamycin plus gentamicin in the treatment of intra-abdominal infections
7. Prospective randomized comparison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis
8. Piperacillin and tazobactam versus clindamycin and gentamicin in the treatment of hospitalized women with pelvic infection
9. Treatment of hospitalized patients with complicated skin and skin structure infections: Double-blind, randomized, multicentre study of piperacillin-tazobactam versus ticarcillin/clavulanate
10. Therapy of soft tissue infections with piperacillin/tazobactam
11. Efficacy and safety of piperacillin/tazobactam in skin and soft tissue infections
12. Efficacy, safety and tolerance of parenteral piperacillin/tazobactam in the treatment of patients with lower respiratory tract infections
13. Piperacillin/tazobactam in the treatment of lower respiratory tract infections: An open non-comparative and multicentered trial
14. Efficacy, safety, tolerance of piperacillin/tazobactam compared to co-amoxiclav plus an aminoglycoside in the treatment of severe pneumonia
15. Piperacillin/tazobactam in complicated urinary tract infections
16. Piperacillin/tazobactam in the treatment of hospitalized patients with urinary tact infections: An open non-comparative and multicentered trial
17. Piperacillin/tazobactam vs. piperacillin/tazobactam plus amikacin as empiric therapy for fever in neutropenic patients
18. Piperacillin/tazobactam versus cefepime as initial empirical antimicrobial therapy in febrile neutropenic patients. A prospective, randomized pilot study
19. Monotherapy with piperacillin/tazobactam versus combination therapy with ceftazidime plus amikacin as an empiric therapy for fever in neutropenic cancer patients
20. Intra-abdominal infections
21. Treatment of intra-abdominal infections
22. Piperacillin/tazobactam: An updated review of its use in the treatment of bacterial infections
23. Clinical efficacy and cost effectiveness of piperacillintazobactam vs ampicillin, gentamicin, and metronidazole in the treatment of intra-abdominal infections
24. Prospective randomized study of piperacillin/tazobactam therapy of surgically treated intra-abdominal infection
25. Piperacillin/tazobactam compared with cefuroxime/metronidazole in the treatment of intra-abdominal infections
26. A randomized comparative study of sulbactam plus ampicillin vs. metronidazole and cefotaxime in the management of acute appendicitis in children
27. Perioperative prophylaxis with sulbactam and ampicillin compared with metronidazole and cefotaxime in the prevention of wound infection in children undergoing appendectomy
28. Emerging resistance to antimicrobial agents in gram-positive bacteria. Enterococci, staphylococci and nonpneumococcal streptococci
29. Colonisation and infection with resistant gram-positive cocci. Epidemiology and risk factors
30. Antimicrobial resistance with focus on betalactam resistance in gram-negative bacilli
31. Beta-lactamases responsible for resistance to expanded-spectrum cephalosporins in Klebsiella pneumoniae, Escherichia coli, and Proteus mirabilis isolates recovered in South Africa
32. Antimicrobial agents. General considerations
33. Piperacillin/tazobactam: A new beta-lactam/beta-lactamase inhibitor combination
34. Antimicrobial chemotherapy
35. Beta-lactamase inhibition: Therapeutic implications in infectious diseases - An overview
36. An open, multicenter clinical trial of piperacillin/tazobactam in the treatment of pediatric patients with intra-abdominal infections